Data from the Reduction of End Points in NIDDM with the Angiotensin II Receptor Antagonist Losartan (RENAAL) study revealed that in patients with T2DM while blood pressure was controlled, hemoglobin (Hb) level is an independent risk factor that predict loss of kidney function and ESRD [125]. This evidence concerns the gene GSTM1 and type 2 diabetes mellitus.